No profile data available.
Immatics N.v. (IMTX) is a healthcare company in the additional cancer treatment drugs industry, based in Tübingen, Germany, with about 704 full-time employees.
It reported revenue of 48.27 million EUR for fiscal year 2025, down 69.0% from fiscal year 2024, and net income of -196.45 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 9.14 million EUR, up 93.0% from a year before. Its market capitalization was $1.13 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Immatics reported 48.27 million EUR in revenue for fiscal year 2025, down 69.0% from 155.84 million EUR in fiscal year 2024. In Q2 2026 revenue was 9.14 million EUR.
$1.13 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Replimune Group, Inc. (REPL), Oric Pharmaceuticals, Inc. (ORIC), Bicara Therapeutics Inc. (BCAX), Janux Therapeutics, Inc. (JANX).